By JBizNews Desk

GENEVA — May 29, 2026 — The World Health Organization (WHO) said Thursday that all vaccines and treatments being considered for the fast-growing Ebola outbreak in the Democratic Republic of the Congo (DRC) should be used only within clinical trials, a decision that leaves health officials without a proven vaccine against the strain driving the outbreak and raises the cost and complexity of containment efforts.

The outbreak, officially declared by the DRC Ministry of Health on May 15, is being caused by the Bundibugyo strain of the Ebola virus, one of the rarer and less-studied members of the Ebola family. More than 130 deaths and hundreds of suspected cases have been reported, according to health agencies and aid organizations operating in the region.

The challenge facing global health officials is that the world’s two approved Ebola vaccines, including Merck’s Ervebo, were developed specifically for the Zaire Ebola virus, the strain responsible for the devastating West African epidemic between 2014 and 2016. Neither vaccine is licensed for Bundibugyo, and evidence that they provide meaningful protection against the strain remains limited.

As a result, WHO convened its R&D Blueprint advisory groups and the Strategic Advisory Group of Experts on Immunization (SAGE) to review available options.

Their conclusion was cautious: any use of existing vaccines should occur only within structured clinical trials capable of generating reliable data on whether they actually work against Bundibugyo.

Health officials fear that deploying a vaccine without clear evidence of effectiveness could create a false sense of security among frontline workers and affected communities.

“There is currently insufficient evidence to support broad deployment outside carefully monitored research settings,” WHO advisors concluded.

Despite the uncertainty, some scientists see reasons for optimism.

Laboratory studies and animal research have suggested that Ervebo may provide at least partial protection against Bundibugyo. Some researchers argue that in the absence of a strain-specific vaccine, testing existing tools is preferable to relying solely on traditional containment methods.

Others remain skeptical.

A separate debate has emerged around a potential “prime-boost” strategy involving experimental vaccines developed for the related Sudan Ebola strain. Some virologists have questioned whether combining different vaccine approaches would produce meaningful protection or simply complicate the response.

IAVI, the nonprofit vaccine developer led by Mark Feinberg, has said it possesses clinical-grade supplies of a Sudan-strain vaccine candidate and would make doses available if requested by health authorities.

The uncertainty highlights a broader weakness in global pandemic preparedness.

While substantial resources were devoted to developing vaccines against the Zaire strain following the 2014-2016 epidemic, far less investment went toward other Ebola variants that appear less frequently but remain capable of causing deadly outbreaks.

The financial consequences are already mounting.

Without a proven vaccine, health officials must rely on labor-intensive containment measures including contact tracing, isolation, surveillance, protective equipment distribution, and safe burial practices.

The European Commission has committed €7.4 million to support WHO-led research and clinical trial efforts, while a WHO logistics hub in Dakar, Senegal, has already delivered 6.3 metric tons of supplies to affected areas, including protective gear, medicines, and diagnostic equipment.

Those expenses are rising because the outbreak is occurring in one of the most challenging environments in the world for disease control.

The affected region in northeastern Congo is already grappling with armed conflict, displacement, weak infrastructure, and limited healthcare capacity. Cases have also been reported in neighboring Uganda, raising concerns about cross-border transmission.

Past Ebola outbreaks have shown that economic damage can extend well beyond public health.

Cross-border trade often slows dramatically, agricultural production declines, consumer activity weakens, and healthcare systems divert resources away from routine care to focus on outbreak response.

Aid group Médecins Sans Frontières (MSF) has reported nearly 500 suspected cases across multiple health zones, making the current crisis one of the largest Ebola outbreaks recorded in recent years.

The absence of a Bundibugyo-specific vaccine also prevents officials from using one of the most effective tools developed during previous outbreaks: ring vaccination.

That strategy involves vaccinating confirmed patients’ contacts and the contacts of those contacts, creating a protective barrier around transmission chains. Ring vaccination helped contain previous Zaire-strain outbreaks efficiently and at relatively low cost, but it depends on having a vaccine proven to work against the circulating virus.

For now, health officials are relying on the same tools used before Ebola vaccines existed: rapid detection, patient isolation, contact tracing, safe burials, and protective equipment.

WHO’s position leaves the door open for experimental vaccines to be tested during the outbreak, but only under scientific protocols designed to provide definitive answers.

The hope is that containment measures succeed before the virus spreads further. The risk is that the world finds itself confronting a deadly Ebola strain without the pharmaceutical tools needed to stop it quickly.

Global Health — JBizNews Desk

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.